DexCom, Inc. (NASDAQ:DXCM) Position Increased by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 53.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,459 shares of the medical device company’s stock after purchasing an additional 6,425 shares during the period. Harvest Fund Management Co. Ltd’s holdings in DexCom were worth $1,237,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in DXCM. Jennison Associates LLC increased its stake in DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares during the last quarter. Westfield Capital Management Co. LP increased its stake in DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after purchasing an additional 876,739 shares during the last quarter. Canada Pension Plan Investment Board increased its stake in DexCom by 189.1% during the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after purchasing an additional 435,401 shares during the last quarter. Intech Investment Management LLC increased its stake in DexCom by 2,083.0% during the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock valued at $25,967,000 after purchasing an additional 369,587 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after purchasing an additional 353,019 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $77.83 on Tuesday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $30.40 billion, a price-to-earnings ratio of 46.60, a PEG ratio of 2.23 and a beta of 1.17. The firm has a 50-day moving average of $70.76 and a two-hundred day moving average of $88.93.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on DXCM shares. Robert W. Baird upped their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. Stifel Nicolaus upped their price target on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Barclays lowered their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Oppenheimer lowered their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Raymond James lowered their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.